Neurodegenerative Disorder Therapeutics Market Sees a Silver Lining with Cell and Gene Therapies

The market is expected to reach $15.44 billion by 2024 at a CAGR of 8.30% with improvements in early disease diagnosis, finds Frost & Sullivan October 28, 2019 – With both large pharmaceutical companies and mid-sized biotechs adopting emerging technologies such as artificial intelligence and machine learning, there has been a reorientation of drug discovery and development, validation, testing, and clinical deployment. Scientific advancements such as cell and gene therapies and understanding of the microbiome, plus improvements in early disease diagnostics, are expected to drive the $9.56 billion neurodegenerative disorder (ND) therapeutics market for Alzheimer's and Parkinson's Diseases (AD/PD) toward $15.44 billion in 2024 at a compound annual growth rate (CAGR) of 8.30%. "With the alarming attrition rate of clinical pipeline for Alzheimer's and Parkinson's, and elusive success of therapies in their ability to modify disease, the future of the therapy hinges on the course of action companies take today," said Khushbu Jain, Transformational Health Industry Analyst. "As the understanding of science behind disease deepens and offers new pathways for drug development, pharma companies will have to seek additional avenues for revenue and unconventional partnerships to offer immediate solutions to patients. The most lucrative partners remain digital platform providers that can help manage the disease better, help expedite drug discovery and, ultimately, deliver on outcome-based care."